TITLE

Report: PrEP effective with just a few doses, but no new strategies

AUTHOR(S)
SIMONETTE, MATT
PUB. DATE
July 2014
SOURCE
Windy City Times;7/30/2014, Vol. 29 Issue 44, p8
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article talks about a study published in the journal "The Lancet Infectious Diseases" that reveals the 90 percent chances of HIV infection reduction by taking as few as two or three doses of Pre-Exposure Prophlaxis or PrEP a week while taking four or more doses offers a 100-percent reduction.
ACCESSION #
97342941

 

Related Articles

  • Correspondence. Smith, Davey; Joseph Wong // Clinical Infectious Diseases;2/15/2002, Vol. 34 Issue 4, p553 

    Comments on an article regarding the continuation of antiretroviral therapy (ARV) for patients who have virologic failure. Resistance-associated mutations associated with virologic failure; Effect of continuing the ARV therapy.

  • Correspondence. Smith, Davey; Joseph Wong // Clinical Infectious Diseases;2/15/2002, Vol. 34 Issue 4, p553 

    Comments on an article regarding the continuation of antiretroviral therapy (ARV) for patients who have virologic failure. Resistance-associated mutations associated with virologic failure; Effect of continuing the ARV therapy.

  • Clinical digest. Diabetes patients benefit from antiviral treatment for hepatitis C infection.  // Nursing Standard;1/29/2014, Vol. 28 Issue 22, p16 

    The article discusses the article "Antiviral Treatment for Hepatitis C Virus Infection Is Associated With Improved Renal and Cardiovascular Outcomes in Diabetic Patients" by Y. Hsu et al. in the journal "Hepatology" which found that diabetes patients benefit from antiviral treatment for...

  • Awareness and Use of HIV Pre-Exposure Prophylaxis Among Attendees of a Seattle Gay Pride Event and Sexually Transmitted Disease Clinic. Barash, Elizabeth Anne; Golden, Matthew // AIDS Patient Care & STDs;Nov2010, Vol. 24 Issue 11, p689 

    We surveyed a convenience sample of 215 HIV-negative men who have sex with men (MSM) recruited at a Gay Pride event and in an STD clinic about their willingness to use pre-exposure prophylaxis (PrEP). Overall, 44% reported that they would take PrEP every day if it helped prevent HIV. There was...

  • Drugs Five Years Later: Acyclovir. Dorsky, David I.; Crumpacker, Clyde S. // Annals of Internal Medicine;Dec87, Vol. 107 Issue 6, p859 

    Provides information on a study which examined the efficacy of the acyclovir therapy and its compatibility with other antiviral drugs in the era of antiviral therapy. Uses of the therapy; Assessment of the major adverse effect of acyclovir; Requirement of the antiviral drug; Implication of the...

  • Treatment of Chronic Hepatitis B. Lagget, M.; M. Rizzetto, M. // Current Pharmaceutical Design;May2002, Vol. 8 Issue 11, p953 

    Infection with the hepatitis B virus has switched over the last 20 years from the classical HBeAg positive serologic pattern to a HBeAg negative form that is linked, in the Mediterranean basin, with the epidemiologic replacement of the causative wild-type of virus B with mutant variants, whereby...

  • Stop Herpes Outbreaks Before They Start. Eastman, Peggy // Self;Mar99, Vol. 21 Issue 3, p112 

    Reports the use of antiviral drugs to suppress the outbreaks of genital herpes. Details on herpes; Example of antiviral drugs that can be used to combat the outbreaks.

  • One-day famciclovir = three-day valacyclovir.  // Critical Care Alert;Nov2008 Pharmacology Watch, p2 

    The article presents an overview of the study on recurrent genital herpes treatment with the use of famciclovir and valacyclovir.

  • More Direct-Acting Antivirals for Treatment of Hepatitis C. Winslow, Dean L. // Infectious Disease Alert;Oct2013, Vol. 33 Issue 1, p3 

    Faldepravir (a HCV protease inhibitor) Fand deleobuvir (a nonnucleoside polymerase inhibitor) were studied in a phase 2b randomized, open-label trial. 362 patients, all with previously untreated HCV genotype 1 infection were randomly assigned to 5 groups: Faldepravir (FDV) 120 mg daily plus...

  • Lamivudine holds promise for hepatitis B.  // Modern Medicine;Sep98, Vol. 66 Issue 9, p49 

    Studies the therapeutic effect of lamivudine, antiviral drug intended for HIV, in treating hepatitis B. Details on the study; Adverse effect of the drug.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics